180 related articles for article (PubMed ID: 2239806)
1. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia.
Paciucci PA; Davis RB; Holland JF; Martelo O; Schiffer CA
Am J Clin Oncol; 1990 Dec; 13(6):516-9. PubMed ID: 2239806
[TBL] [Abstract][Full Text] [Related]
2. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
Paciucci PA; Cuttner J; Holland JF
Am J Hematol; 1990 Sep; 35(1):22-5. PubMed ID: 2202204
[TBL] [Abstract][Full Text] [Related]
3. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
4. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
Thomas X; Cambier N; Taksin AL; Reman O; Vekhoff A; Pautas C; Leblond V; Soler-Michel P; Ecstein-Fraïssé E; Archimbaud E
Leuk Res; 2000 Nov; 24(11):957-63. PubMed ID: 11086179
[TBL] [Abstract][Full Text] [Related]
6. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
[TBL] [Abstract][Full Text] [Related]
7. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
Archimbaud E; Leblond V; Michallet M; Cordonnier C; Fenaux P; Travade P; Dreyfus F; Jaubert J; Devaux Y; Fiere D
Blood; 1991 May; 77(9):1894-900. PubMed ID: 2018832
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
O'Brien S; Kantarjian H; Estey E; Koller C; Beran M; McCredie K; Keating M
Cancer; 1991 Aug; 68(4):691-4. PubMed ID: 1855168
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
Paciucci PA; Dutcher JP; Cuttner J; Strauman JJ; Wiernik PH; Holland JF
Leukemia; 1987 Jul; 1(7):565-7. PubMed ID: 3478540
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
Lazzarino M; Morra E; Alessandrino EP; Orlandi E; Pagnucco G; Merante S; Bernasconi P; Inverardi D; Bonfichi M; Bernasconi C
Eur J Haematol; 1989 Nov; 43(5):411-6. PubMed ID: 2612614
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Kornblau SM; Estey E; Madden T; Tran HT; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman RA; Andreeff M
J Clin Oncol; 1997 May; 15(5):1796-802. PubMed ID: 9164187
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
[TBL] [Abstract][Full Text] [Related]
14. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
[TBL] [Abstract][Full Text] [Related]
16. Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia.
Kaminer LS; Choi KE; Daley KM; Larson RA
Cancer; 1990 Jun; 65(12):2619-23. PubMed ID: 2340463
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia.
Link H; Freund M; Diedrich H; Wilke H; Austein J; Henke M; Wandt H; Fackler-Schwalbe E; Schlimok G; Hoffmann R
Haematol Blood Transfus; 1990; 33():322-5. PubMed ID: 2182426
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
20. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
